The Treatment of Myeloid Malignancies with Kinase Inhibitors, An Issue of Hematology/Oncology Clinics of North America
- 1 Edición, Volumen 31-4 - 14 de julio de 2017
- Última edición
- Autor: Ann Mullally
- Idioma: Inglés
This issue of Hematology/Oncology Clinics will focus on The Treatment of Myeloid Malignancies with Kinase Inhibitors. Articles will focus on: Targeting aberrant signaling in… Leer más
Descripción
Descripción
This issue of Hematology/Oncology Clinics will focus on The Treatment of Myeloid Malignancies with Kinase Inhibitors. Articles will focus on: Targeting aberrant signaling in myeloid malignancies: promise versus reality; The development and use of imatinib for the treatment of chronic myelogenous leukemia; Mechanisms of resistance to ABL kinase inhibition in CML and the development of next generation ABL kinase inhibitors; Tyrosine kinase inhibitors in the treatment of systemic mastocytosis and hypereosinophilic syndrome; The development and use of JAK2 inhibitors for the treatment of myeloproliferative neoplasms (MPN); Mechanisms of resistance to JAK2 inhibitors in MPN; Kinase inhibitor screening in myeloid malignancies; and more!
Detalles del producto
Detalles del producto
- Edición: 1
- Última edición
- Volumen: 31-4
- Publicado: 14 de julio de 2017
- Idioma: Inglés
Sobre el autor
Sobre el autor
AM
Ann Mullally
Afiliaciones y experiencia
Dana-Farber/Brigham and Women's Cancer Center